Lacosamide
Rank #173 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$90.1M
Total Cost
300,038
Total Claims
$90.1M
Total Cost
7,587
Prescribers
$300
Cost per Claim
26,440
Beneficiaries
364,890
30-Day Fills
$12K
Avg Cost/Provider
40
Avg Claims/Provider
Share of Medicare Part D Spending
0.03%
of total Medicare Part D spending
$90.1M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $90.1M total
Top Prescribers of Lacosamide
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Jessica Bishop | Physician Assistant | Boise, ID | 388 | $541K |
| 2 | Ignacio Pita Garcia | Neurology | Guaynabo, PR | 354 | $478K |
| 3 | Deborah Zielinski | Nurse Practitioner | Chicago, IL | 178 | $305K |
| 4 | Toufic Fakhoury | Neurology | Lexington, KY | 227 | $298K |
| 5 | Gregory Connor | Neurology | Tulsa, OK | 1,122 | $257K |
| 6 | Jason Bisping | Neurology | Columbus, OH | 110 | $235K |
| 7 | Toufic Fakhoury | Neurology | Lexington, KY | 1,088 | $217K |
| 8 | Deborah Risbrook | Nurse Practitioner | New Hyde Park, NY | 126 | $201K |
| 9 | George Morris | Neurology | Milwaukee, WI | 113 | $200K |
| 10 | Bethany Thomas | Nurse Practitioner | Philadelphia, PA | 86 | $169K |
| 11 | Kelly Pearson-Caravetta | Nurse Practitioner | Philadelphia, PA | 688 | $159K |
| 12 | Samir Al-Kabbani | Neurology | Knoxville, TN | 128 | $154K |
| 13 | Julie Hanna | Neurology | Roseville, MN | 414 | $152K |
| 14 | Kevin Graber | Neurology | Stanford, CA | 265 | $145K |
| 15 | Louann Carnahan | Neurology | Tucson, AZ | 104 | $145K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 170 | Insulin Glargine/Lixisenatide (Soliqua 100-33) | $92.5M | 82,886 |
| 171 | Latanoprost (Latanoprost) | $92.3M | 4,388,601 |
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
| 176 | Ixazomib Citrate (Ninlaro) | $89.0M | 6,901 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology